Victory Capital Management Inc. raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 177.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,468 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,058 shares during the period. Victory Capital Management Inc.’s holdings in Jazz Pharmaceuticals PLC were worth $1,385,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. FMR LLC increased its position in shares of Jazz Pharmaceuticals PLC by 11.4% during the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after acquiring an additional 849,348 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Jazz Pharmaceuticals PLC by 3.4% during the second quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock valued at $727,308,000 after acquiring an additional 153,908 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Jazz Pharmaceuticals PLC by 41.2% during the second quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after acquiring an additional 410,031 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Jazz Pharmaceuticals PLC by 3.5% during the second quarter. Renaissance Technologies LLC now owns 1,201,500 shares of the specialty pharmaceutical company’s stock valued at $186,833,000 after acquiring an additional 40,537 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Jazz Pharmaceuticals PLC by 11,990.7% during the second quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock valued at $135,894,000 after acquiring an additional 866,691 shares in the last quarter. 90.52% of the stock is owned by institutional investors.

In related news, Director Patrick G. Enright sold 351 shares of Jazz Pharmaceuticals PLC stock in a transaction on Friday, August 25th. The shares were sold at an average price of $148.40, for a total transaction of $52,088.40. Following the transaction, the director now owns 1,717 shares in the company, valued at approximately $254,802.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Patrick G. Enright sold 352 shares of Jazz Pharmaceuticals PLC stock in a transaction on Friday, November 17th. The shares were sold at an average price of $133.19, for a total transaction of $46,882.88. Following the transaction, the director now owns 1,365 shares in the company, valued at approximately $181,804.35. The disclosure for this sale can be found here. Insiders have sold a total of 10,703 shares of company stock worth $1,469,851 in the last quarter. Corporate insiders own 4.30% of the company’s stock.

Several equities research analysts recently weighed in on JAZZ shares. Deutsche Bank AG set a $175.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Wednesday, August 9th. Royal Bank Of Canada reissued a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Janney Montgomery Scott reissued a “buy” rating and set a $192.00 price target (up previously from $180.00) on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Zacks Investment Research raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $174.00 price target for the company in a research report on Tuesday, August 8th. Finally, Cowen and Company set a $190.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Monday, August 21st. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $180.13.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at $137.19 on Wednesday. The firm has a market cap of $8,169.46, a price-to-earnings ratio of 17.10, a PEG ratio of 0.81 and a beta of 1.00. Jazz Pharmaceuticals PLC has a one year low of $99.28 and a one year high of $163.75. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/victory-capital-management-inc-has-1-39-million-holdings-in-jazz-pharmaceuticals-plc-jazz/1719224.html.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.